These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 31111505)

  • 21. Pharmacokinetic-Pharmacodynamic Evaluation of Gepotidacin against Gram-Positive Organisms Using Data from Murine Infection Models.
    Bulik CC; Okusanya ÓO; Lakota EA; Forrest A; Bhavnani SM; Hoover JL; Andes DR; Ambrose PG
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872075
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic and pharmacodynamic aspects of oral moxifloxacin 400 mg/day in elderly patients with acute exacerbation of chronic bronchitis.
    Pea F; Pavan F; Lugatti E; Dolcet F; Talmassons G; Screm MC; Furlanut M
    Clin Pharmacokinet; 2006; 45(3):287-95. PubMed ID: 16509760
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Do We Bury Antibacterials When Launching? Cefaclor Example.
    Tomić Z; Tomas A; Vukmirović S; Mikov M; Horvat O; Tomić N; Sabo A
    J Pharm Sci; 2016 Mar; 105(3):1295-300. PubMed ID: 26886327
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics.
    Nightingale CH
    Pharmacotherapy; 2000 Mar; 20(3):245-56. PubMed ID: 10730681
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Temocillin dosing in haemodialysis patients based on population pharmacokinetics of total and unbound concentrations and Monte Carlo simulations.
    Miranda Bastos AC; Vandecasteele SJ; Spinewine A; Tulkens PM; Van Bambeke F
    J Antimicrob Chemother; 2018 Jun; 73(6):1630-1638. PubMed ID: 29579214
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activity of newer fluoroquinolones against gram-positive and gram-negative bacteria isolated from ocular infections: an in vitro comparison.
    Duggirala A; Joseph J; Sharma S; Nutheti R; Garg P; Das T
    Indian J Ophthalmol; 2007; 55(1):15-9. PubMed ID: 17189881
    [TBL] [Abstract][Full Text] [Related]  

  • 27. What Antibiotic Exposures Are Required to Suppress the Emergence of Resistance for Gram-Negative Bacteria? A Systematic Review.
    Sumi CD; Heffernan AJ; Lipman J; Roberts JA; Sime FB
    Clin Pharmacokinet; 2019 Nov; 58(11):1407-1443. PubMed ID: 31325141
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Monte Carlo pharmacokinetic/pharmacodynamic simulation to evaluate the efficacy of minocycline, tigecycline, moxifloxacin, and levofloxacin in the treatment of hospital-acquired pneumonia caused by Stenotrophomonas maltophilia.
    Wei C; Ni W; Cai X; Cui J
    Infect Dis (Lond); 2015; 47(12):846-51. PubMed ID: 26167850
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of moxifloxacin for community-acquired bacterial pneumonia based on pharmacokinetic analysis.
    Yoshida K; Okimoto N; Kishimoto M; Fukano H; Hara H; Yoneyama H; Moriya O; Kawanishi M; Kimura M; Matsushima T; Niki Y
    J Infect Chemother; 2011 Oct; 17(5):678-85. PubMed ID: 21847518
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population Pharmacokinetics of Colistin Methanesulfonate and Colistin in Critically Ill Patients with Acute Renal Failure Requiring Intermittent Hemodialysis.
    Jacobs M; Grégoire N; Mégarbane B; Gobin P; Balayn D; Marchand S; Mimoz O; Couet W
    Antimicrob Agents Chemother; 2016 Jan; 60(3):1788-93. PubMed ID: 26729492
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic/pharmacodynamic target attainment of intravenous β-lactam regimens against Gram-negative bacteria isolated in a Brazilian teaching hospital.
    Furtado GH; Cardinal L; Macedo RS; Silva JO; Medeiros EA; Kuti JL; Nicolau DP
    Rev Soc Bras Med Trop; 2015; 48(5):539-45. PubMed ID: 26516962
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A pharmacometric approach to define target site-specific breakpoints for bacterial killing and resistance suppression integrating microdialysis, time-kill curves and heteroresistance data: a case study with moxifloxacin.
    Iqbal K; Broeker A; Nowak H; Rahmel T; Nussbaumer-Pröll A; Österreicher Z; Zeitlinger M; Wicha SG
    Clin Microbiol Infect; 2020 Sep; 26(9):1255.e1-1255.e8. PubMed ID: 32088331
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
    Roos JF; Bulitta J; Lipman J; Kirkpatrick CM
    J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Population Pharmacokinetics and Pharmacodynamic Target Attainment of Ampicillin in Neonates with Hypoxemic-Ischemic Encephalopathy in the Setting of Controlled Hypothermia.
    Cies JJ; Fugarolas KN; Moore WS; Mason RW; Menkiti OR
    Pharmacotherapy; 2017 Apr; 37(4):456-463. PubMed ID: 28226400
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen.
    Georges B; Conil JM; Cougot P; Decun JF; Archambaud M; Seguin T; Chabanon G; Virenque C; Houin G; Saivin S
    Int J Clin Pharmacol Ther; 2005 Aug; 43(8):360-9. PubMed ID: 16119511
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Developments in the pharmacokinetic/pharmacodynamic index of linezolid: a step toward dose optimization using Monte Carlo simulation in critically ill patients.
    Dong H; Xie J; Chen L; Wang T; Sun J; Zhao Y; Dong Y
    Int J Infect Dis; 2014 May; 22():35-40. PubMed ID: 24603161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic and Pharmacodynamic Profiling of Minocycline for Injection following a Single Infusion in Critically Ill Adults in a Phase IV Open-Label Multicenter Study (ACUMIN).
    Lodise TP; Van Wart S; Sund ZM; Bressler AM; Khan A; Makley AT; Hamad Y; Salata RA; Silveira FP; Sims MD; Kabchi BA; Saad MA; Brown C; Oler RE; Fowler V; Wunderink RG
    Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33168615
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of the Microbiological Efficacy of a Single 2-Gram Dose of Extended-Release Azithromycin by Population Pharmacokinetics and Simulation in Japanese Patients with Gonococcal Urethritis.
    Soda M; Ito S; Matsumaru N; Nakamura S; Nagase I; Takahashi H; Ohno Y; Yasuda M; Yamamoto M; Tsukamoto K; Itoh Y; Deguchi T; Kitaichi K
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038284
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Declining susceptibilities of gram-negative bacteria to the fluoroquinolones: effects on pharmacokinetics, pharmacodynamics, and clinical outcomes.
    Labreche MJ; Frei CR
    Am J Health Syst Pharm; 2012 Nov; 69(21):1863-70. PubMed ID: 23111670
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.